Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Merck Sharp & Dohme Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (146)
Australian public assessment report (AusPar) (4)

Date

2018 (1)
2017 (13)
2016 (38)
2015 (87)
2014 (11)

Search

Sponsor content

150 result(s) found, displaying 61 to 70

PEGATRON COMBINATION THERAPY peginterferon alfa-2b (rbe) 120 microgram powder for injection/capsule/diluent composite pack Cancelled under s30(1)(c) of the Act

4 December 2015

Cancellation by sponsor

Requested by Merck Sharp & Dohme Australia Pty Ltd
PEGATRON COMBINATION THERAPY peginterferon alfa-2b (rbe) 150 microgram powder for injection/capsule/diluent composite pack Cancelled under s30(1)(c) of the Act

4 December 2015

Cancellation by sponsor

Requested by Merck Sharp & Dohme Australia Pty Ltd
VICTRELIS PEGATRON COMBINATION THERAPY Peg-Intron Redipen (4 x 50mcg) + Rebetol (112 capsules) + Victrelis (336 capsules) Cancelled under s30(1)(c) of the Act

4 December 2015

Cancellation by sponsor

Requested by Merck Sharp & Dohme Australia Pty Ltd
VICTRELIS PEGATRON COMBINATION THERAPY Peg-Intron Redipen (4 x 100mcg) + Rebetol (112 capsules) + Victrelis (336 capsules) Cancelled under s30(1)(c) of the Act

4 December 2015

Cancellation by sponsor

Requested by Merck Sharp & Dohme Australia Pty Ltd
VICTRELIS PEGATRON COMBINATION THERAPY Peg-Intron Redipen (4 x 120mcg) + Rebetol (140 capsules) + Victrelis (336 capsules) Cancelled under s30(1)(c) of the Act

4 December 2015

Cancellation by sponsor

Requested by Merck Sharp & Dohme Australia Pty Ltd
VICTRELIS PEGATRON COMBINATION THERAPY Peg-Intron Redipen (4 x 150mcg) + Rebetol (140 capsules) + Victrelis (336 capsules) Cancelled under s30(1)(c) of the Act

4 December 2015

Cancellation by sponsor

Requested by Merck Sharp & Dohme Australia Pty Ltd
VELMETIA 50mg/500mg sitagliptin phosphate monohydrate / metformin hydrochloride 50 mg/500mg tablet blister pack Cancelled under s30(1)(c) of the Act

6 November 2015

Cancellation by sponsor

Requested by Merck Sharp & Dohme Australia Pty Ltd
VELMETIA 50mg/850mg sitagliptin phosphate monohydrate / metformin hydrochloride 50mg/850mg tablet blister pack Cancelled under s30(1)(c) of the Act

6 November 2015

Cancellation by sponsor

Requested by Merck Sharp & Dohme Australia Pty Ltd
VELMETIA 50mg/1000mg sitagliptin phosphate monohydrate / metformin hydrochloride 50mg/1000mg tablet blister pack Cancelled under s30(1)(c) of the Act

6 November 2015

Cancellation by sponsor

Requested by Merck Sharp & Dohme Australia Pty Ltd
VELMETIA XR 50/500 sitagliptin (as phosphate monohydrate)/metformin hydrochloride 50 mg/500 mg extended release tablet bottle Cancelled under s30(1)(c) of the Act

6 November 2015

Cancellation by sponsor

Requested by Merck Sharp & Dohme Australia Pty Ltd

Pages

First page
Previous page
…
Page 3
Page 4
Page 5
Page 6
Current page 7
Page 8
Page 9
Page 10
Page 11
…
Next page
Last page

Is there anything wrong with this page?

Help us improve

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.